LYS006

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Colitis, UlcerativeHidradenitis SuppurativaNon-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis

Phase 2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active, not recruitingNCT03827798

Novartis PharmaceuticalsHidradenitis Suppurativa

Start: 2019-02-27End: 2026-12-11Updated: 2026-02-06

Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis

TerminatedNCT04074590

Novartis PharmaceuticalsColitis, Ulcerative

Start: 2020-02-03End: 2022-11-07Updated: 2024-06-20

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

TerminatedNCT04147195

Novartis PharmaceuticalsNon-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis

Start: 2020-06-04End: 2022-01-06Updated: 2023-08-21

Related Papers

Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis.

2025-11-26